Immuron Limited
IMRNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeImmuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. With a market capitalization of $9.8M, it sits in micro-cap territory. It operates through two segments, Research and Development; and Hyper-immune Products.
Market Cap
$9.8M
Beta
0.50
P/E (TTM)
—
P/E (Fwd)
-122.00
EPS (TTM)
$-0.53
EPS (Fwd)
$-0.01
ROE
-39.7%
ROA
-21.9%
Cash
$10.0M
Total Debt
$203,914
Free CF
-$3.4M
52W Change
-28.2%
Annual Financials
Cash vs Debt
Where IMRN stands vs its 150-day and 200-day moving averages
As of the July 10, 2026 close, IMRN finished 32.63% above its 150-day moving average ($0.95) and 5.88% above its 200-day moving average ($1.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMRN overbought or oversold?
At the July 10, 2026 close, IMRN's RSI(14) was 66.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $10.0M in cash comfortably exceeding the $204K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$3.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -39.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $765K (2022) to $7.3M (2025), reflecting a 852% increase over the period.
IMRN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, IMRN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing IMRN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.